Mabpharm Ltd (02181.HK)価格

Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu and currently employs 383 full-time employees. The company went IPO on 2019-05-31. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The firm is also engaged in the transfer of intellectual property. The firm mainly conducts its business in the domestic market.